[HTML] mdpi.com

[HTML][HTML] Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic

P Dlouhý, C Mucha, L Mokrá, M Kuhn… - Journal of Clinical …, 2024 - mdpi.com
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was
introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of …
相关文章

Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic

P Dlouhý, C Mucha, L Mokrá… - Journal of clinical …, 2024 - pubmed.ncbi.nlm.nih.gov
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was
introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of …
[HTML] nih.gov

[HTML][HTML] Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic

P Dlouhý, C Mucha, L Mokrá, M Kuhn… - Journal of Clinical …, 2024 - ncbi.nlm.nih.gov
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was
introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of …

Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic.

P Dlouhý, C Mucha, L Mokrá, M Kuhn… - Journal of Clinical …, 2024 - search.ebscohost.com
Abstract Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment,
was introduced in the Czech Republic in December 2021 for COVID-19 patients at a high …

Molnupiravir Real-World Utilization in COVID-19 Patients in the Czech Republic.

P Dlouhý, C Mucha, L Mokrá, M Kuhn… - Journal of Clinical …, 2024 - europepmc.org
Background/Objectives: Molnupiravir (MOV), an oral antiviral COVID-19 treatment, was
introduced in the Czech Republic in December 2021 for COVID-19 patients at a high risk of …